O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases
Clinical Trial Application approval…Read More
You might also be interested in reading Leading Digital Asset Bank Selects Tezos for Financial Services Products.